148 related articles for article (PubMed ID: 21077036)
1. [Consolidation therapy in advanced non-small cell lung cancer].
Duchnowska R
Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Silvestri GA; Rivera MP
Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
[TBL] [Abstract][Full Text] [Related]
3. [EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Reck M; Kranich AL; Steinbach AK; Gatzemeier U
Med Klin (Munich); 2005 Dec; 100(12):785-93. PubMed ID: 16453093
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Ramalingam S; Belani C
Oncologist; 2008; 13 Suppl 1():5-13. PubMed ID: 18263769
[TBL] [Abstract][Full Text] [Related]
6. Salvage with erlotinib plus bevacizumab: not in NSCLC.
Sculier JP; Meert AP; Berghmans T
Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
[No Abstract] [Full Text] [Related]
7. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Cortot AB
Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
[TBL] [Abstract][Full Text] [Related]
8. Optimal duration of chemotherapy in advanced non-small cell lung cancer.
Lustberg MB; Edelman MJ
Curr Treat Options Oncol; 2007 Feb; 8(1):38-46. PubMed ID: 17634834
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
[TBL] [Abstract][Full Text] [Related]
10. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Baselga J
J Clin Oncol; 2004 Mar; 22(5):759-61. PubMed ID: 14990627
[No Abstract] [Full Text] [Related]
11. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
12. Histology matters: individualizing treatment in non-small cell lung cancer.
Neal JW
Oncologist; 2010; 15(1):3-5. PubMed ID: 20086166
[TBL] [Abstract][Full Text] [Related]
13. Salvage therapy in patients with advanced non-small cell lung cancer.
Bedano PM; Hanna NH
J Thorac Oncol; 2006 Jul; 1(6):582-7. PubMed ID: 17409922
[TBL] [Abstract][Full Text] [Related]
14. Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Wakelee HA
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):17-21. PubMed ID: 24852399
[No Abstract] [Full Text] [Related]
15. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology Group.
Jalal S; Waterhouse D; Edelman MJ; Nattam S; Ansari R; Koneru K; Clark R; Richards A; Wu J; Yu M; Bottema B; White A; Hanna N
J Thorac Oncol; 2009 Nov; 4(11):1420-4. PubMed ID: 19701110
[TBL] [Abstract][Full Text] [Related]
18. Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Takemura Y; Chihara Y; Morimoto Y; Tanimura K; Imabayashi T; Seko Y; Kaneko Y; Date K; Ueda M; Arimoto T; Iwasaki Y; Takayama K
Anticancer Res; 2018 Apr; 38(4):2385-2390. PubMed ID: 29599365
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Yu CT; Ganul V; Roh JK; Bajetta E; O'Byrne K; de Marinis F; Eberhardt W; Goddemeier T; Emig M; Gatzemeier U;
Lancet; 2009 May; 373(9674):1525-31. PubMed ID: 19410716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]